Medicure Inc. (TSXV:MPH)

Market Cap	27.76M +141.8%
Revenue (ttm)	32.08M +38.3%
Net Income	-7.45M
EPS	-0.72
Shares Out	10.44M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,700
Open	2.660
Previous Close	2.690
Day's Range	2.660 - 2.660
52-Week Range	0.850 - 2.740
Beta	1.27
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 23, 2026

About Medicure

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 38
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: MPH

Financial Performance

In 2025, Medicure's revenue was 28.86 million, an increase of 31.72% compared to the previous year's 21.91 million. Losses were -7.10 million, 583.1% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 18, 2026

Data Sources Report a data error